Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 1 of 16
ValiRx signs service deal with TheoremRx; expects VAL201 sub-licence completion by end-Q1
ValiRx had previously expected to receive the first payments from the intended sub-licence with TheoremRx by the end of 2021
ValiRx inks new deal with Physiomics for cancer and coronavirus (COVID-19) programmes
“Enhancing the scientific understanding of our results using cutting edge technology ensures we maximise the value of the data we have collected," said VariRX chief executive Suzy Dilly.
ValiRx working on options to hold a meeting to vote on vital cash lifeline
The company adjourned the general meeting that was to be held on 25 March 2020 as a result of the COVID-19 situation
ValiRx says its treatment had a “clear impact on patients with prostate cancer”
The drug developer was at pains to stress this was only a very preliminary inference from the data measuring prostate-specific antigens and supported by tumour imagin
ValiRx updates on JV discussions and switches NOMAD
The company said it also expects to receive a tax credit shortly
Archive
Proactive news snapshot: Digitalbox, Seeing Machines, Alba Minerals Resources...
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx wins European patent protection for potential endometriosis treatment
VAL301 is in pre-clinical development as a non-invasive, effective treatment for endometriosis, which affects roughly 5-10% of women in their reproductive years
Archive
Rose Petroleum leaps as energy investor Jon Fitzpatrick picks up 5% stake in the company
A look at the day's major movers, including Xeros Technology Group, Redx Pharma, Bango, PageGroup, Hays, Jaywing and One Media iP Group
Archive
Proactive news snapshot: Redx Pharma, Feedback, Bango, SIMEC Atlantis …
A glance at some of the day's highlights from the Proactive Investors newswire